SSA
NERV icon

Schonfeld Strategic Advisors’s Minerva Neurosciences NERV Stock Holding History

Schonfeld Strategic Advisors’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,266
Closed -$90K – 723
2017
Q2 		$90K Buy
+1,266
New +$81.9K 0.01% 576
2016
Q4 		– Sell
-2,560
Closed -$289K – 616
2016
Q3 		$289K Buy
+2,560
New +$248K 0.05% 321

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AC
Ascend Capital Orinda, California $1.99B AUM 10.36% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Schonfeld Strategic Advisors's NERV Position: Q3 2017 in Review

Schonfeld Strategic Advisors sold out of Minerva Neurosciences (NERV) in Q3 2017, closing a stake of 1,266 shares — an estimated $90K sold.

Schonfeld Strategic Advisors first reported a position in NERV in Q3 2016 and held it in 2 quarters. The position peaked at $289K in Q3 2016. 70 funds tracked by Wall St. Rank hold NERV as of Q3 2017.

  • Schonfeld Strategic Advisors reported no remaining Minerva Neurosciences position as of Q3 2017 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 1,266 Minerva Neurosciences shares in Q3 2017, an estimated $90K.
  • Schonfeld Strategic Advisors first reported a position in Minerva Neurosciences in Q3 2016 and held it in 2 quarters.
  • Schonfeld Strategic Advisors's Minerva Neurosciences position peaked at $289K in Q3 2016.
  • 70 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q3 2017.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.